for people ages 12 months to 21 years (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Official Title

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors


Pediatric Solid Tumor Refractory Tumor Recurrent Tumor CNS Malignancies relapsed pediatric solid tumors unspecified childhood solid tumor brain and central nervous system tumors Neoplasms Endothelial Growth Factors Ramucirumab


You can join if…

Open to people ages 12 months to 21 years

  • Part A: participants with recurrent or refractory non-CNS solid tumors
  • Part B: participants with recurrent or refractory CNS tumors
  • Measurable or evaluable disease
  • No other therapeutic options
  • Performance Status: Karnofsky ≥50% for participants >16 years and Lansky ≥50 for participants ≤16 years

You CAN'T join if...

  • Active or recent history of serious bleeding events
  • Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
  • Active or recent history of hypertensive crisis or hypertensive encephalopathy
  • Active non-healing wound or bone fracture
  • History of solid organ transplant


  • University of California, San Francisco accepting new patients
    San Francisco California 94158 United States
  • Children's Oncology Group accepting new patients
    Monrovia California 91016 United States
  • Childrens Hospital of Orange County accepting new patients
    Orange California 92868 United States


accepting new patients
Start Date
Completion Date
Eli Lilly and Company
Click here for more information about this study: A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
Phase 1
Study Type
Last Updated
September 11, 2018